Updated Jul 16, 2026 · Last SEC filing 2026-07-02
Emergent BioSolutions Inc. (EBS) has filed 21 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-02. 3 Form 8-K material event filings were reported by EBS in the last 90 days. 5 Form 144 notices of proposed sale were filed for EBS stock. InsiderAlpha tracks every EBS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001367644 |
| Form 4 filings (90d) | 21 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 5 |
| Latest Form 4 filing | 2026-07-02 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Williams Paul Anthony | SVP, Products Business | S — Open-market sale | 3.0K | $8.40 | $25K | SEC | |
| Williams Paul Anthony | SVP, Products Business | F — Tax withholding / forfeiture | 694 | $8.00 | $6K | SEC | |
| LINDAHL RICHARD S | EVP, Chief Financial Officer | F — Tax withholding / forfeiture | 4.0K | $8.00 | $32K | SEC | |
| Glessner Coleen | EVP, Quality & Ethics, and CPL | F — Tax withholding / forfeiture | 2.0K | $8.00 | $16K | SEC | |
| Hartzel William | SVP, Bioservices | F — Tax withholding / forfeiture | 1.7K | $8.00 | $14K | SEC | |
| DeGolyer Donald W | Director | S — Open-market sale | 14.5K | $8.36 | $121K | SEC | |
| Zoon Kathryn C | Director | S — Open-market sale | 16.1K | $8.36 | $135K | SEC | |
| Zoon Kathryn C | Director | S — Open-market sale | 1.1K | $8.97 | $9K | SEC | |
| Dayal Sujata Tyagi | Director | S — Open-market sale | 12.8K | $8.36 | $107K | SEC | |
| Dayal Sujata Tyagi | Director | S — Open-market sale | 980 | $8.94 | $9K | SEC | |
| DeGolyer Donald W | Director | S — Open-market sale | 954 | $8.96 | $9K | SEC | |
| DeGolyer Donald W | Director | A — Grant or award | 25.3K | $0.00 | — | SEC | |
| Richard Ronald | Director | A — Grant or award | 25.3K | $0.00 | — | SEC | |
| Zoon Kathryn C | Director | A — Grant or award | 25.3K | $0.00 | — | SEC | |
| Dayal Sujata Tyagi | Director | A — Grant or award | 25.3K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Emergent BioSolutions Inc. (EBS). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Dayal Sujata Tyagi | 4 | $116K |
| DeGolyer Donald W | 4 | $130K |
| Zoon Kathryn C | 4 | $144K |
| Katkin Keith | 3 | $128K |
| Williams Paul Anthony | 3 | $31K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in EBS insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live EBS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.